Compare SGMT & OTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SGMT | OTAI |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 136.6M |
| IPO Year | 2021 | 2026 |
| Metric | SGMT | OTAI |
|---|---|---|
| Price | $7.79 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $26.13 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 47.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $9.92 |
| 52 Week High | $11.41 | $10.73 |
| Indicator | SGMT | OTAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 80.19 |
| Support Level | $7.04 | $9.92 |
| Resistance Level | $8.80 | $10.73 |
| Average True Range (ATR) | 0.50 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 74.60 | 20.48 |
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Starlink AI Acquisition Corp is a blank check company.